Login to Your Account

With Positive Data In CABG, Dyax Offering Raises $41M

By Randall Osborne

Monday, January 5, 2004
On the heels of positive early Phase I/II data for bleeding control during coronary artery bypass graft (CABG) surgery, Dyax Corp. said it has agreed to sell about 5.2 million shares for $7.93 each, raising about $41.4 million pursuant to a shelf registration. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription